Autoimmune-mediated reduction of high-density lipoprotein-cholesterol and paraoxonase 1 activity in systemic lupus erythematosus-prone gld mice

Arthritis and Rheumatism

Volumn 63, Issue 1, 2011, Pages 201-211

  Srivastava, Roshni ^a,b   Yu, Shaohua ^a,b   Parks, Brian W ^a,b   Black, Leland L ^a   Kabarowski, Janusz H ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE 1; CHOLESTEROL ESTER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LYSOPHOSPHATIDYLCHOLINE; SERUM AMYLOID A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; AUTOIMMUNITY; BIOGENESIS; CHOLESTEROL BLOOD LEVEL; CLINICAL EVALUATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; LYMPHOID ORGAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

AGING; ANALYSIS OF VARIANCE; ANIMALS; ARYLDIALKYLPHOSPHATASE; AUTOANTIBODIES; AUTOIMMUNITY; BLOTTING, WESTERN; CHOLESTEROL, HDL; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTES; MICE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 78650772175     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27764     Document Type: Article

References (48)

1. Lewis GF, Rader DJ,. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 2005; 96: 1221-32.
2. Shih DM, Lusis AJ,. The roles of PON1 and PON2 in cardiovascular disease and innate immunity. Curr Opin Lipidol 2009; 20: 288-92.
3. Cuchel M, Rader DJ,. Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? Circulation 2006; 113: 2548-55.
4. Gabay C, Kushner I,. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-54.
5. Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR, et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004; 45: 1169-96.
6. Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response: loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995; 96: 2758-67.
7. Feingold KR, Memon RA, Moser AH, Grunfeld C,. Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis 1998; 139: 307-15.
8. Van der Westhuyzen DR, de Beer FC, Webb NR,. HDL cholesterol transport during inflammation. Curr Opin Lipidol 2007; 18: 147-51.
9. Coetzee GA, Strachan AF, van der Westhuyzen DR, Hoppe HC, Jeenah MS, de Beer FC,. Serum amyloid A-containing human high density lipoprotein 3: density, size, and apolipoprotein composition. J Biol Chem 1986; 261: 9644-51.
10. Sorenson RC, Bisgaier CL, Aviram M, Hsu C, Billecke S, La Du BN,. Human serum paraoxonase/arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity. Arterioscler Thromb Vasc Biol 1999; 19: 2214-25.
11. Kindy MS, de Beer MC, Yu J, de Beer FC,. Expression of mouse acute-phase (SAA1.1) and constitutive (SAA4) serum amyloid A isotypes: influence on lipoprotein profiles. Arterioscler Thromb Vasc Biol 2000; 20: 1543-50.
12. Khovidhunkit W, Moser AH, Shigenaga JK, Grunfeld C, Feingold KR,. Regulation of scavenger receptor class B type I in hamster liver and Hep3B cells by endotoxin and cytokines. J Lipid Res 2001; 42: 1636-44.
13. McGillicuddy FC, de la Llera Moya M, Hinkle CC, Joshi MR, Chiquoine EH, Billheimer JT, et al. Inflammation impairs reverse cholesterol transport in vivo. Circulation 2009; 119: 1135-45.
14. Wilhelm AJ, Zabalawi M, Grayson JM, Weant AE, Major AS, Owen J, et al. Apolipoprotein A-I and its role in lymphocyte cholesterol homeostasis and autoimmunity. Arterioscler Thromb Vasc Biol 2009; 29: 843-9.
15. Bensinger SJ, Bradley MN, Joseph SB, Zelcer N, Janssen EM, Hausner MA, et al. LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell 2008; 134: 97-111.
16. Smith JD,. Dysfunctional HDL as a diagnostic and therapeutic target. Arterioscler Thromb Vasc Biol 2010; 30: 151-5.
17. Bruce IN,. 'Not onlyâ∥but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford) 2005; 44: 1492-502.
18. 2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis Rheum 2002; 46: 2686-94.
19. Batuca JR, Ames PR, Isenberg DA, Alves JD,. Antibodies toward high-density lipoprotein components inhibit paraoxonase activity in patients with systemic lupus erythematosus. Ann N Y Acad Sci 2007; 1108: 137-46.
20. McMahon M, Grossman J, FitzGerald J, Dahlin-Lee E, Wallace DJ, Thong BY, et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006; 54: 2541-9.
21. - C57BL/6 mice: a novel murine model simultaneously exhibits lupus nephritis, atherosclerosis, and osteopenia. J Lipid Res 2007; 48: 794-805.
22. Stanic AK, Stein CM, Morgan AC, Fazio S, Linton MF, Wakeland EK, et al. Immune dysregulation accelerates atherosclerosis and modulates plaque composition in systemic lupus erythematosus. Proc Natl Acad Sci U S A 2006; 103: 7018-23.
23. Daugherty A,. Mouse models of atherosclerosis. Am J Med Sci 2002; 323: 3-10.
24. Mahley RW, Rall SC Jr., Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 2000; 1: 507-37.
25. Parks BW, Lusis AJ, Kabarowski JH,. Loss of the lysophosphatidylcholine effector, G2A, ameliorates aortic atherosclerosis in low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol 2006; 26: 2703-9.
26. Parks BW, Srivastava R, Yu S, Kabarowski JH,. ApoE-dependent modulation of HDL and atherosclerosis by G2A in LDL receptor-deficient mice independent of bone marrow-derived cells. Arterioscler Thromb Vasc Biol 2009; 29: 539-47.
27. Parks BW, Gambill GP, Lusis AJ, Kabarowski JH,. Loss of G2A promotes macrophage accumulation in atherosclerotic lesions of low-density lipoprotein receptor-deficient mice. J Lipid Res 2005; 46: 1405-15.
28. Kabarowski JH,. G2A and LPC: regulatory functions in immunity. Prostaglandins Other Lipid Mediat 2009; 89: 73-81.
29. Le LQ, Kabarowski JH, Weng Z, Satterthwaite AB, Harvill ET, Jensen ER, et al. Mice lacking the orphan G protein-coupled receptor G2A develop a late-onset autoimmune syndrome. Immunity 2001; 14: 561-71.
30. 2-like activity and lysophosphatidylcholine formation. Arterioscler Thromb Vasc Biol 2003; 23: 461-7.
31. Hahn BH,. Should antibodies to high-density lipoprotein cholesterol and its components be measured in all systemic lupus erythematosus patients to predict risk of atherosclerosis? [editorial]. Arthritis Rheum 2010; 62: 639-42.
32. Qiao JH, Xie PZ, Fishbein MC, Kreuzer J, Drake TA, Demer LL, et al. Pathology of atheromatous lesions in inbred and genetically engineered mice: genetic determination of arterial calcification. Arterioscler Thromb 1994; 14: 1480-97.
33. Gu L, Johnson MW, Lusis AJ,. Quantitative trait locus analysis of plasma lipoprotein levels in an autoimmune mouse model: interactions between lipoprotein metabolism, autoimmune disease, and atherogenesis. Arterioscler Thromb Vasc Biol 1999; 19: 442-53.
34. Kelley VE, Roths JB,. Interaction of mutant lpr gene with background strain influences renal disease. Clin Immunol Immunopathol 1985; 37: 220-9.
35. Osmers I, Smith SS, Parks BW, Yu S, Srivastava R, Wohler JE, et al. Deletion of the G2A receptor fails to attenuate experimental autoimmune encephalomyelitis. J Neuroimmunol 2009; 207: 18-23.
36. 2. J Lipid Res 2010; 51: 743-54.
37. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN,. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions: a possible peroxidative role for paraoxonase. J Clin Invest 1998; 101: 1581-90.
38. 2 and atherosclerosis. Curr Opin Lipidol 2009; 20: 415-20.
39. Tetta C, Bussolino F, Modena V, Montrucchio G, Segoloni G, Pescarmona G, et al. Release of platelet-activating factor in systemic lupus erythematosus. Int Arch Allergy Appl Immunol 1990; 91: 244-56.
40. Cederholm A, Svenungsson E, Stengel D, Fei GZ, Pockley AG, Ninio E, et al. Platelet-activating factor-acetylhydrolase and other novel risk and protective factors for cardiovascular disease in systemic lupus erythematosus. Arthritis Rheum 2004; 50: 2869-76.
41. Gomes RN, Bozza FA, Amancio RT, Japiassu AM, Vianna RC, Larangeira AP, et al. Exogenous platelet-activating factor acetylhydrolase reduces mortality in mice with systemic inflammatory response syndrome and sepsis. Shock 2006; 26: 41-9.
42. Yang J, Xu J, Chen X, Zhang Y, Jiang X, Guo X, et al. Decrease of plasma platelet-activating factor acetylhydrolase activity in lipopolysaccharide induced Mongolian gerbil sepsis model. PLoS One 2010; 5: e9190.
43. Wu R, Svenungsson E, Gunnarsson I, Andersson B, Lundberg I, Schafer Elinder L, et al. Antibodies against lysophosphatidylcholine and oxidized LDL in patients with SLE. Lupus 1999; 8: 142-50.
44. Deakin S, Moren X, James RW,. HDL oxidation compromises its influence on paraoxonase-1 secretion and its capacity to modulate enzyme activity. Arterioscler Thromb Vasc Biol 2007; 27: 1146-52.
45. Nguyen SD, Sok DE,. Preferable stimulation of PON1 arylesterase activity by phosphatidylcholines with unsaturated acyl chains or oxidized acyl chains at sn-2 position. Biochim Biophys Acta 2006; 1758: 499-508.
46. McMahon M, Grossman J, Skaggs B, FitzGerald J, Sahakian L, Ragavendra N, et al. Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum 2009; 60: 2428-37.
47. Jahangiri A, de Beer MC, Noffsinger V, Tannock LR, Ramaiah C, Webb NR, et al. HDL remodeling during the acute phase response. Arterioscler Thromb Vasc Biol 2009; 29: 261-7.
48. 2 promotes scavenger receptor class B type I interaction and accelerates HDL catabolism. J Lipid Res 2000; 41: 1849-57.